Ma Yinglong's share reform

Wuhan Ma Yinglong Pharmaceutical Group Co., Ltd. was established on1May 9, 1994 and registered in Wuhan Administration for Industry and Commerce. The company, formerly known as Wuhan No.3 Pharmaceutical Factory, was approved by the Wuhan Economic System Reform Commission with the document "No.5 [1993] 189", and was established by directional fundraising. On March 20th, 2004, with the approval of China Securities Regulatory Commission's Notice on Approving the Public Offering of Wuhan Ma Yinglong Pharmaceutical Group Co., Ltd. (Z.J.K. Zi (2004) No.40), the company publicly issued 65,438+0,800,000 RMB ordinary shares to the public, and it was listed on Shanghai Stock Exchange on May 65,438+07, 2004. After this issuance, the company's share capital increased to 565,438+065,438+069,740 shares, including 9 million state shares, 23,578,880 legal person shares, 590,860 individual shares and 654,380 RMB ordinary shares. On August 13, 2004, Wuhan Huahan Investment Management Co., Ltd. and Wuhan Donghu Innovation and Technology Investment Co., Ltd. signed the Legal Person Share Transfer Contract. Wuhan Huahan Investment Management Co., Ltd. transferred its 2.6 million legal person shares to Wuhan Donghu Innovation and Technology Investment Co., Ltd. at a price of 9.4 1 yuan per share.

On March 19, 2005, Wuhan Donghu Innovation and Technology Investment Co., Ltd. transferred its 3.8 million legal person shares (accounting for 7.43% of the company's total share capital) to Wuhan Huahan Investment Management Co., Ltd., a shareholder of the company, and completed the transfer registration procedures of legal person shares on June 3, 2005.

On July 9, 2006, the company implemented the share-trading reform, and the tradable shares were changed from the original180,000 shares to 2 16974 shares, and the non-tradable shares were changed from the original 33 16974 shares to 2956974 shares with limited sales conditions.

On May 9, 2007, the profit distribution plan for 2006 was reviewed and approved by the 2006 annual general meeting of shareholders. Based on the total share capital of 5 1 and169,740 shares at the end of 2006, two shares of 3 yuan (including tax) were distributed for every 10 share, and the share capital of the company was changed to 6 1.

The Company was reviewed and approved by the 2007 annual general meeting of shareholders, and changed its name from Wuhan Ma Yinglong Pharmaceutical Group Co., Ltd. to Ma Yinglong Pharmaceutical Group Co., Ltd. on May 6, 2008. The corresponding industrial and commercial approval and industrial and commercial change procedures for the change of company name have all been completed. The company obtained a new business license in Wuhan Administration for Industry and Commerce on May 30, 2008, and the new official seal was put into use on June 2, 2008. Securities abbreviation remains unchanged.